CANCER CHEMOTHERAPY AND PHARMACOLOGY

Edit Your Profile

CANCER CHEMOTHERAPY AND PHARMACOLOGY Journal

publication venue for

A phase 1 and pharmacodynamic study of chronically-dosed, single-agent veliparib (ABT-888) in patients with BRCA1- or BRCA2-mutated cancer or platinum-refractory ovarian or triple-negative breast cancer. 89:721-735. 2022
A phase i dose-escalation trial of 2-deoxy-d-glucose alone or combined with docetaxel in patients with advanced solid tumors. 71:523-530. 2013
A multicenter phase II study of docetaxel, oxaliplatin, and bevacizumab in first-line therapy for unresectable locally advanced or metastatic non-squamous cell histology non-small-cell lung cancer (NSCLC). 72:1103-1110. 2013
Phase I and pharmacokinetic study of mitomycin C and celecoxib as potential modulators of tumor resistance to irinotecan in patients with solid malignancies. 63:1073-1082. 2009
A phase I study of gemcitabine plus palliative radiation therapy for advanced lung cancer. 63:175-179. 2008
Effect of dalteparin and radiation on survival and thromboembolic events in glioblastoma multiforme: a phase II ECOG trial. 62:227-233. 2008
Thalidomide and celecoxib as potential modulators of irinotecan's activity in cancer patients. 59:23-33. 2007
Repression of telomerase reverse transcriptase mRNA and hTERT promoter by gambogic acid in human gastric carcinoma cells. 58:434-443. 2006

category

ONCOLOGY Category
PHARMACOLOGY & PHARMACY Category

International Standard Serial Number (ISSN)

0344-5704

journal abbreviation

CANCER CHEMOTH PHARM